Use test of moisturizer for patients with skin disorder receiving EGFR inhibitor.

Use test of moisturizer for patients with skin disorder receiving EGFR inhibitor. - Use test of moisturizer for patients with skin disorder receiving EGFR inhibitor.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034432

Enrollment

Registered

2018-10-10

Start date

2018-10-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin disorder caused by EGFR inhibitors

Interventions

Use the test moisturizer in combination with treatment.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Lung cancer patients with positive EGFR gene variation Patients receiving gefitinib(Iressa),erlotinib(Tarceva),afatinib(Giotrif),osimertinib(Tagrisso),Cetuximab(Erbitax),Panitumumab(Vectibix) Patients aged of 18 over at the time of enrollment The sex does not matter

Exclusion criteria

Exclusion criteria: Person who experienced skin symptoms such as contact dermatitis due to the ingredients of this research item and similar ingredients In addiction,parson who the research staff judged inappropriate as subjects

Design outcomes

Primary

Measure	Time frame
the safety(5% or less rate of adverse effect)	—

Secondary

Measure	Time frame
Skin physiological verification(changes in skin measurement value and cytokine in epidermal horny layer) Changes in stratum corneum water content,epidermal water transpiration amount,sebum quantity Improvement of QOL and feeling of use of this research product by questionnaire	—

Countries

Japan

Contacts

Public ContactChiharu Tateishi

Osaka city University Hospital Dermatology

tatechiharu@gmail.com06-6645-3826

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026